Long-term interferon alpha maintenance therapy for chronic hepatitis C infection in a patient with common variable immune deficiency

Journal of Clinical Gastroenterology

Volumn 29, Issue 2, 1999, Pages 203-206

  Willson, Richard A ^a,b   Fischer, S H ^a   Ochs, H D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Hepatitis C; Interferon; Primary immunodeficiency

Indexed keywords

ALPHA INTERFERON; IMMUNOGLOBULIN; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; IMMUNE DEFICIENCY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONG TERM CARE; MAINTENANCE THERAPY; PORTAL HYPERTENSION; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; COMMON VARIABLE IMMUNODEFICIENCY; DRUG CONTAMINATION; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPATITIS C, CHRONIC; HUMANS; HYPERTENSION, PORTAL; IMMUNOGLOBULINS, INTRAVENOUS; INTERFERON ALFA-2B; MIDDLE AGED; TIME FACTORS;

EID: 0032775683     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-199909000-00023     Document Type: Article

References (31)

1. Sneller MC, Strober W, Eisenstein E, Jaffe JS, Cunningham-Rundles C. New insights into common variable immunodeficiency. Ann Intern Med 1993;118:720-30.
2. Rosen FS, Cooper MD, Wedgwood RJP. The primary immunodeficiencies. N Engl J Med 1995;333:431-40.
3. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991;325:110-7.
4. Schiff RI. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994;331:1649-50.
5. Ochs HD, Fischer SH, Virant FS, Lee ML, Kingdon HS, Wedgwood RJ. Non-A, non-B hepatitis after intravenous globulin. Lancet 1985;i:404-5.
6. Yap PL, McOmish F, Webster ADB, et al. Hepatitis C virus transmission by intravenous immunoglobulin. J Hepatol 1994;21:455-60.
7. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
8. Gretch DR, de la Rosa C, Carithers RL, Willson RA, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med 1995;123:321-9.
9. Martinot-Peignoux M, Marcellin P, Poutearu M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995;22:1050-6.
10. Thomson BJ, Doran M, Lever AML, Webster ADB. Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy. Lancet 1987;i:539-41.
11. Lockner D, Bratt G, Lindborg A, Tornebohm E. Acute unidentified hepatitis in a hypogammaglobulinemic patient on intravenous gammaglobulin successfully treated with interferon. Acta Med Scand 1987;221:413-5.
12. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-11.
13. Schalm SW, Fattovich G, Brouwer JT. Therapy of hepatitis C: patients with cirrhosis. Hepatology 1997;26(suppl 1):128S-32S.
14. Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-40.
15. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-402.
16. Duchatelle V, Marcellin P, Giostra E, et al. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method. J Hepatol 1998;29:20-8.
17. Hermaszewski RA, Webster ADB. Primary hypogammaglobulinemia: a survey of clinical manifestations and complications. QJM 1993;86:31-42.
18. Quinti I, Pandolfi F, Paganelli R, et al. HCV infection in patients with primary defects of immunoglobulin production. Clin Exp Immunol 1995;102:11-6.
19. Seeff LB. Natural history of hepatitis C. Hepatology 1997;26(suppl 1):21S-8S.
20. Hoofnagle JH, DiBisceglie AM. Drug therapy: the current treatment of viral hepatitis. N Engl J Med 1997;336:347-56.
21. Sarara AI, Hunt CM, Hamilton JD. Hepatitis C update. Ann Intern Med 1996;125:658-68.
22. Healy CJ, Sabharwal NK, Daub J, et al. Outbreak of acute hepatitis C following the use anti-hepatitis C virus-screened, intravenous immunoglobulin therapy. Gastroenterology 1996:110:1120-6.
23. Jonas MM, Baron MJ, Bresee JS, Schneider LC. Clinical and virologie features of hepatitis C virus infection associated with intravenous immunoglobulin. Pediatrics 1996;98:211-5.
24. Fasano MB, Sullivan KE, Sarpong SB, et al. Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature. Medicine 1996;75:251-61.
25. Mechanic LJ, Dikman S, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Ann Intern Med 1997;127:613-7.
26. Morris A, Webster ADB, Brown D, Harrison TJ, Dusheiko G. GB virus infection in patients with primary antibody deficiency. J Infect Dis 1998;177:1719-22.
27. Cunningham-Rundles C. Clinical and immunologic analyses of 103 patients with common variable immunodeficiency. J Clin Immunol 1989;9:22-33.
28. Gane EJ, Portmann BC, Naoumov NV, et al. Long term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-20.
29. Boker KHW, Dalley G, Bahr MJ, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997;25:203-10.
30. Smith MSH, Webster ADB, Dhillon AP, et al. Orthotopic liver transplantation for chronic hepatitis in two patients with common variable immunodeficiency. Gastroenterology 1995;108:879-84.
31. VanThiel DH, Finkel R, Friedlander L, Gavaler JS, Wright HI, Gordon R. The association of IgA deficiency but not IgG or IgM deficiency with a reduced patient and graft survival following liver transplantation. Transplantation 1992;54:269-73.